Pulmonary hypertension (PH) is a complex and progressive disease characterized by elevated pulmonary arterial pressure and pulmonary vascular resistance. This article aims to provide a comprehensive understanding of PH, its pathophysiology, clinical presentation, diagnosis, and management strategies.
PH is primarily a disease of the small pulmonary arteries, which undergo vasoconstriction, vascular remodeling, and thrombosis in situ. These changes lead to increased pulmonary vascular resistance, right ventricular overload, and eventually right heart failure if left untreated.
Patients with PH often present with dyspnea, fatigue, chest pain, syncope, and signs of right heart failure. The diagnosis of PH is made based on a mean pulmonary artery pressure ≥25 mmHg at rest, as measured by right heart catheterization. Additional diagnostic tools include echocardiography, pulmonary function tests, and computed tomography of the chest.
The management of PH is multidimensional and includes general measures, targeted drug therapy, and in severe cases, lung transplantation. General measures include supportive care, physical activity, and supplemental oxygen. Targeted drug therapies aim to reverse the pathophysiological changes in the pulmonary arteries. These include endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclin analogs. Lung transplantation is reserved for patients with advanced disease who fail to respond to medical therapy.
Understanding the fundamentals of PH is crucial for prompt diagnosis and effective management. The complexity of the disease necessitates a multidisciplinary approach and a thorough understanding of its pathophysiology, clinical presentation, and management strategies. By staying abreast of the latest research and treatment modalities, healthcare professionals can provide optimal care for patients with this challenging condition.
1.
Stem Cell Selection Unneeded for SSc Transplant Therapy?
2.
Radiation from CT scans could account for 5% of all cancer cases a year, study suggests
3.
Do I have prostate cancer? Why a simple PSA blood test alone won't give you the answer
4.
In Hemophilia A and B, a Novel Monoclonal Antibody Reduces Bleeding.
5.
Tumor infiltration of major blood vessels, not metastasis, may be primary cause of cancer death
1.
Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization
2.
Emerging Dysregulated Signaling Pathways in Early-Onset Colorectal Cancer
3.
Exploring the Use of Bevacizumab in Treating Different Types of Cancers
4.
A Closer Look at Poorly Differentiated Carcinoma: Uncovering its Complexities
5.
Unlocking the Secrets of Squamous Cell Carcinoma: New Hope for Patients
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
2.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
3.
A New Era in Managing Cancer-Associated Thrombosis
4.
Navigating the Complexities of Ph Negative ALL - Part IX
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation